Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead (Nature Reviews Drug Discovery, (2020), 19, 2, (93-111), 10.1038/s41573-019-0049-9)

Erik Tambuyzer; Benjamin Vandendriessche; Christopher P. Austin; Philip J. Brooks; Kristina Larsson; Katherine I.Miller Needleman; James Valentine; Kay Davies; Stephen C. Groft; Robert Preti; Tudor I. Oprea; Marco Prunotto

ArticleOPEN ACCESS

Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead (Nature Reviews Drug Discovery, (2020), 19, 2, (93-111), 10.1038/s41573-019-0049-9)

Nature Reviews Drug Discovery

DOI: 10.1038/s41573-019-0059-7

3Citations

14Readers

Abstract

The use of the names for patisiran has been made consistent throughout the article in line with the journal style and typographical errors have been corrected.

Cite

CITATION STYLE

APA

Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Needleman, K. I. M., … Prunotto, M. (2020, April 1). Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead (Nature Reviews Drug Discovery, (2020), 19, 2, (93-111), 10.1038/s41573-019-0049-9). Nature Reviews Drug Discovery. Nature Research. https://doi.org/10.1038/s41573-019-0059-7

Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead (Nature Reviews Drug Discovery, (2020), 19, 2, (93-111), 10.1038/s41573-019-0049-9)

Abstract

Cite

Register to see more suggestions